Baird Medical Pioneers ground breaking Thyroid Microwave Ablation in Landmark U.S. Procedure...
Olympus Strengthens its Medical Portfolio with Successful Acquisition of Taewoong Medical Co., Ltd, a Leading Korean Gastrointestinal Stent Company...
Digital channels are emerging as the preferred method for engagement with field teams in Asia...
In a groundbreaking initiative, Fujirebio Holdings, Inc. and Agappe Diagnostics Ltd have joined forces in a Contract Development and Manufacturing Organization (CDMO) collaboration focused on advancing Cartridge-based CLIA system reagents....
Addressing the critical need for automating and standardising tumour response assessments in medical imaging...
Three-year supply contract: Lunit INSIGHT CXR and Lunit INSIGHT CXR Triage to enhance lung abnormality detection in Samsung's premium X-ray devices...
Hospital to monitor all patients digitally with the use of technology and biosensors...
Established in 2000, South Korea based Seegene Inc is a leader in molecular diagnostics and achieved remarkable financial success with over $1 billion in revenue and 65 per cent gross margins. With a mission for a disease-free world and proactive pandemic prevention, Seegene seamlessly integrates high multiplex diagnostic assays with automated testing systems. In an interaction with BioSpectrum & MedTech Spectrum, Dr Seong-Youl Kim, Seegene's Senior Vice President, shares insights on the company...
Since the launch of the global strategy against cervical cancer in 2020, the World Health Organization (WHO) has accelerated the initiative by virtue of commitments and strategies offered by governments and organisations worldwide. Australia is on track to become one of the first nations to achieve this, and countries like Bangladesh and Indonesia have introduced HPV vaccines. Let's examine Asia's efforts in eliminating cervical cancer and whether the continent is on track to meet WHO’s targets ...
Varian, a Siemens Healthineers company, and Nova Scotia Health have formed an unprecedented 10-year, $175 million CAD multi-disciplinary oncology partnership (MDOP) designed to deliver value across the Nova Scotia Health system by accelerating the patient journey from screening to survivorship....
